Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 14, Issue 8, 2008, Pages 1091-1096

  Manfredi, Michael A ^a,b   Zurakowski, David ^a,b   Rufo, Paul A ^a,b   Walker, Thomas R ^a,b   Fox, Victor L ^a,b   Moses, Marsha A ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Karp Family Research Laboratories   (United States)

Author keywords

Biomarkers; Inflammatory bowel disease; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases; Urinary MMPs; Urine test

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SCLEROPROTEIN;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; INCIDENCE; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INVASIVE MEASUREMENT; PATHOGENESIS; PATIENT ASSESSMENT; PEDIATRIC HOSPITAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; ULCERATIVE COLITIS; UNITED STATES; URINALYSIS; ZYMOGRAPHY;

ADOLESCENT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PREDICTIVE VALUE OF TESTS;

EID: 49749130444     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20419     Document Type: Article

References (36)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
2. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006;223-268.
3. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15:180-189.
4. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990;248:1408-1410.
5. Heuschkel RB, MacDonald TT, Monteleone G, et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000;47:57-62.
6. Pender SL, Tickle SP, Docherty AJ, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997;158: 1582-1590.
7. Salmela MT, MacDonald TT, Black D, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut. 2002;51:540-547.
8. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol. 1994;47:113-116.
9. Baugh MD, Evans GS, Hollander AP, et al. Expression of matrix metalloproteases in inflammatory bowel disease. Ann N Y Acad Sci. 1998;859:249-253.
10. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822.
11. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709.
12. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073.
13. Cook-Mills JM. VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol. 2002;39:499-508.
14. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008.
15. Garg P, Rojas M, Ravi A, et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol. 2006; 177:4103-4112.
16. Di Sebastiano P, di Mola FF, Artese L, et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion. 2001;63:234-239.
17. Medina C, Videla S, Radomski A, et al. Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol. 2001;36:1314-1319.
18. Sykes AP, Bhogal R, Brampton C, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzene-sulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:1535-1542.
19. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004; 22:499-506.
20. Fernandez CA, Yan L, Louis G, et al. The matrix metalloproteinase-9/ neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005; 11:5390-5395.
21. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998; 58:1395-1399.
22. Yan L, Borregaard N, Kjeldsen L, et al. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276: 37258-37265.
23. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
24. Bland M. An introduction to medical statistics. New York: Oxford University Press; 2000.
25. Fleiss JL, Tytun A, Urg HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics. 1980; 343-346.
26. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 2000.
27. Gao Q, Meijer MJ, Kubben FJ, et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis. 2005;37:594-592.
28. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10:445-456.
29. Nielsen BS, Borregaard N, Bundgaard JR, et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38:414-420.
30. Tarlton JF, Whiting CV, Tunmore D, et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a marine model of colitis. Am J Pathol. 2000;157:1927-1935.
31. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
32. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
33. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child. 1995; 73:354-355.
34. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985;148:105-109.
35. Khan K, Schwarzenberg SJ, Sharp H, et al. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:325-329.
36. Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989; 56:126-130.